El interés en corto de 10x Genomics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de 10x Genomics. Los datos de interés en corto se actualizan cada dos semanas.

10x Genomics (NASDAQ:TXG) Bolsa, Informe de interés en corto

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Equities

News

ETFs

ACHR

ARKK

PLTR

QCOM

RBLX

Ark Invest vendió acciones de Palantir por 10,4M$. ¿Qué impulsó esta decisión y qué significa para los inversionistas?

Ark Invest ajusta su portafolio: venta masiva de Palantir y nuevas compras estratégicas

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

DA Davidson analyst Peter Heckmann maintains CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) with a Buy and raises the price target from $36 to $38.

Price Target

Analyst Ratings

PMTS

DA Davidson Maintains Buy on CPI Card, Raises Price Target to $38

LTRY

Lottery.com Announces Ad-Supported Model

CIBC analyst Paul Holden maintains Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) with a Outperformer and lowers the price target from C$96 to C$95.

TSX:TD

CIBC Maintains Outperformer on Toronto-Dominion Bank, Lowers Price Target to C$95

Macro Economic Events

Politics

Economics

General

President Trump Says He Spoke To Trudeau About Tariffs; The Call Ended In A "Somewhat" Friendly Manner; Fentanyl Efforts Not Good Enough

B of A Securities analyst Ruplu Bhattacharya maintains Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy and lowers the price target from $30 to $28.

INGM

B of A Securities Maintains Buy on Ingram Micro Holding, Lowers Price Target to $28

CIBC analyst Paul Holden maintains Royal Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RY#TSX">RY</a>) with a Neutral and lowers the price target from C$175 to C$167.

TSX:RY

CIBC Maintains Neutral on Royal Bank of Canada, Lowers Price Target to C$167

B of A Securities analyst Alec Stranahan maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Neutral and lowers the price target from $14 to $12.

YMAB

B of A Securities Maintains Neutral on Y-mAbs Therapeutics, Lowers Price Target to $12

B of A Securities analyst Tim Anderson maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and raises the price target from $159 to $171.

B of A Securities Maintains Neutral on Johnson & Johnson, Raises Price Target to $171

Telsey Advisory analyst Dana Telsey <a target="_blank" href="https://www.benzinga.com/quote/ROST/analyst-ratings" rel="noreferrer noopener">reiterated a Market Perform</a> rating on the shares of Ross Stores Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) and lowered the price forecast from $175.00 to $150.00.
ROST <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44125245/ross-stores-reports-results-for-fourth-quarter-and-fiscal-2024" rel="noreferrer noopener">reported fourth-quarter EPS of $1.79</a>, slightly lower than last year&#8217;s $1.82 but above both the consensus estimate and guidance of $1.57 &#8211; $1.64.
The earnings beat was largely driven by a $0.14 one-time gain from the sale of a packaway facility. Sales decreased by 1.8% to $5.912 billion, slightly missing consensus.
Comps grew 3%, outperforming the 2.6% consensus. Gross margin contracted to 26.5%, below estimates, but better cost control led to an operating margin of 12.4%, beating expectations, said the analyst.
The analyst noted that ROST&#8217;s initial FY25 outlook falls short of expectations. Total sales are projected to grow 1% &#8211; 5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/25/03/44143576/apples-latest-macbook-air-with-m4-chip-is-twice-as-fast-as-its-predecessor-with-lower-price" rel="noreferrer noopener">Apple&#8217;s Latest MacBook Air With M4 Chip Is Twice As Fast As Its Predecessor With Lower Price</a>
FY25 EPS is estimated to be between $5.95 &#8211; $6.55, lower than the $6.32 reported in FY24 and below the consensus of $6.67.
ROST&#8217;s first-quarter FY25 guidance is also below expectations. Sales are projected to decline 1% to increase by 3%, compared to the prior consensus of a 6% rise, with comps expected to fall between -3% and 0%, below the consensus of 2.4%.
While the company saw growth in traffic and basket size, sales slowed toward the end of the fourth quarter and continued to decelerate into the first quarter due to unseasonable weather and an uncertain macro environment.
Given these challenges, the first-quarter and FY25 outlooks are conservative. The company faces pressure from shifts affecting its core lower-income customers.
As a result, the analyst has lowered FY25 sales growth outlook to 4.6% YoY growth to $22.09 billion (from up 5.7% to $22.33 billion prior). EPS estimate for FY25 has been moved down to $6.54 (vs. $6.70 previously).
Price Action: ROST shares are trading higher by 1.38% at $137.84 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44140237/coreweave-acquires-weights-biases-to-enhance-ai-development" target="_blank" rel="noreferrer noopener">Nvidia Backed CoreWeave Acquires AI Developer Platform Weights &amp; Biases</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Reiteration

Trading Ideas

ROST

Ross Stores Faces Slower Growth With Shifts In Lower-Income Customers Preference, Says Analyst

CIBC analyst Paul Holden maintains Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) with a Outperformer and lowers the price target from C$156 to C$152.

TSX:BMO

CIBC Maintains Outperformer on Bank of Montreal, Lowers Price Target to C$152

B of A Securities analyst Tim Anderson maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Buy and raises the price target from $116 to $126.

GILD

B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $126

B of A Securities analyst Tim Anderson maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Underperform and raises the price target from $275 to $294.

AMGN

B of A Securities Maintains Underperform on Amgen, Raises Price Target to $294

Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) analysts highlight the sports betting and iGaming market share growth of the company after fourth-quarter <a href="https://www.benzinga.com/general/entertainment/25/03/44140332/flutter-reports-mixed-q4-projects-1-billion-buyback-in-fy25-amid-strong-igaming-momentum">financial results and guidance.</a>
The Flutter Analysts: Citizens analyst Jordan Bender maintained a Market Outperform rating on Flutter and raised the price target from $311 to $328.
Benchmark analyst Mike Hickey reiterated a Buy rating and raised the price target from $275 to $300.
Needham analyst Bernie McTernan reiterated a Buy rating and raised the price target from $300 to $310.
Read Also:<a href="https://www.benzinga.com/25/02/43598736/super-bowl-commercials-2025-complete-list-of-super-bowl-lix-ads-and-companies-behind-them"> Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them</a>
Citizens on FLUT: The sports betting and iGaming company is in the early stages of "substantial earnings power," Bender said in a new investor note.
The analyst said Flutter is the top way to own gaming.
"In a tough quarter for the U.S. business, it still increased market share for both iGaming and sports betting, and early 1Q25 results imply further market share gains across both business segments," Bender said.
The analyst said acquisitions in international markets and the launch of legalized sports betting in Missouri and potentially Alberta, Canada, could improve guidance.
"Consumer stocks are under pressure with the global macro headwinds, yet the company continues to see organic revenue and EBITDA grow meaningfully above similar comps."
Bender said the company's strong balance sheet opens the door for more M&amp;A activity.
Benchmark on FLUT: The company's FanDuel business had strength in the quarter, Hickey said in a new investor note.
"The company achieved significant earnings transformation, with AEBITDA increasing 26%, driven by the rapid scaling of its U.S. business," Hickey said.
The analyst said early first-quarter results show a strong Super Bowl performance offsetting negative NFL results in January.
"The guidance reflects continued U.S. market expansion, the integration of strategic acquisitions, and a robust outlook for international markets."
New launches in Missouri and Alberta could impact EBITD, but are part of long-term market share growth, the analyst said.
Needham on FLUT: Despite tough comparable sales and foreign exchange currency concerns, McTernan is raising the price target on Flutter stock.
"U.S. handle trends have been a focus for investors, and 1Q growth is reaccelerating from 4Q levels," McTernan said.
The fourth quarter was impacted by one less week of the NFL season and a slowing of new state launches.
FanDuel rolling out YourWay is driving engagement in the early stages, McTernan said.
"FLUT has still yet to market the product aggressively, but thinks it can drive higher hold, engagement, and frequency for users. In addition, FLUT is in the early stages of rolling out YourWay for the NBA."
McTernan said Flutter is positioned to be the leader in U.S. online sports betting and iGaming. The analyst said the total addressable market size for the U.S. market is larger than anticipated, benefitting Flutter.
"We see significant earnings power for the consolidated business if this thesis plays out."
FLUT Price Action: Flutter stock is up 1.06% to $268.96 on Wednesday versus a 52-week trading range of $174.03 to $299.73. Flutter stock is up 4.2% year-to-date in 2025 and up 24% over the past year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/02/43572273/why-sportsbooks-like-draftkings-may-favor-low-scoring-super-bowl-lix">Why Sportsbooks Like DraftKings May Favor Low-Scoring Super Bowl LIX</a></li>
</ul>
Photo: Courtesy Flutter Entertainment

Gaming

Sports Betting

FLUT

Flutter Stock Undervalued After Q4 Results, Guidance: Analyst Says 'Earnings Transformation' Underway

CIBC analyst Paul Holden maintains Bank of Nova Scotia (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BNS#TSX">BNS</a>) with a Neutral and lowers the price target from C$81 to C$75.

TSX:BNS

CIBC Maintains Neutral on Bank of Nova Scotia, Lowers Price Target to C$75

B of A Securities analyst Ken Hoexter maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $565 to $484.

SAIA

B of A Securities Maintains Buy on Saia, Lowers Price Target to $484

WIIM

STLA

Shares of Ford, GM and Stellantis are trading higher following a report indicating President Trump held a call with CEOs on a potential auto tariff delay.  Investors may be assessing Trump's plans to make interest payments on car loans tax deductible for US-made vehicles.

B of A Securities analyst Ken Hoexter maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and lowers the price target from $170 to $150.

B of A Securities Maintains Buy on XPO, Lowers Price Target to $150

High-rolling investors have positioned themselves bullish on Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in COST often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 15 options trades for Costco Wholesale. This is not a typical pattern.
The sentiment among these major traders is split, with 13% bullish and 0% bearish. Among all the options we identified, there was one put, amounting to $34,120, and 14 calls, totaling $3,789,748.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $500.0 to $1075.0 for Costco Wholesale over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Costco Wholesale's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Costco Wholesale's substantial trades, within a strike price spectrum from $500.0 to $1075.0 over the preceding 30 days.
<h3>Costco Wholesale Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741197677_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$536.4</td>
<td>$530.1</td>
<td>$533.24</td>
<td>$500.00</td>
<td>$533.2K</td>
<td align="right">81</td>
<td align="right">10</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$536.4</td>
<td>$530.1</td>
<td>$533.21</td>
<td>$500.00</td>
<td>$533.2K</td>
<td align="right">81</td>
<td align="right">30</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$465.95</td>
<td>$457.65</td>
<td>$461.8</td>
<td>$570.00</td>
<td>$369.4K</td>
<td align="right">30</td>
<td align="right">24</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$465.95</td>
<td>$457.65</td>
<td>$461.8</td>
<td>$570.00</td>
<td>$369.4K</td>
<td align="right">30</td>
<td align="right">8</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$465.9</td>
<td>$457.65</td>
<td>$461.71</td>
<td>$570.00</td>
<td>$369.3K</td>
<td align="right">30</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About Costco Wholesale</h3>
Costco operates a membership-based, no-frills retail model, predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given Costco's frugal cost structure, the firm is able to price its merchandise below competing retailers, driving high sales volume per warehouse and allowing the retailer to generate strong profits on thin margins. Costco operates over 600 warehouses in the United States and boasts over 60% market share in the domestic warehouse club industry. Internationally, Costco operates another 280 warehouses, primarily in markets such as Canada, Mexico, Japan, and the UK.
In light of the recent options history for Costco Wholesale, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Costco Wholesale's Current Market Status</h3>
<ul>
<li>With a trading volume of 592,258, the price of COST is up by 0.28%, reaching $1039.74.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 1 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Costco Wholesale</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1069.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Outperform rating for Costco Wholesale, targeting a price of $1100. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Costco Wholesale, targeting a price of $1070. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Costco Wholesale with a target price of $1075. 
&#x2A; An analyst from Telsey Advisory Group has decided to maintain their Outperform rating on Costco Wholesale, which currently sits at a price target of $1100. 
&#x2A; An analyst from DA Davidson has decided to maintain their Neutral rating on Costco Wholesale, which currently sits at a price target of $1000. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Costco Wholesale with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

COST

Behind the Scenes of Costco Wholesale's Latest Options Trends

Investors with significant funds have taken a bearish position in Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in CVNA usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for Carvana. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 25% being bullish and 62% bearish. Of all the options we discovered, 7 are puts, valued at $533,280, and there was a single call, worth $136,740.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $125.0 to $230.0 for Carvana over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Carvana stands at 4513.5, with a total volume reaching 1,825.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Carvana, situated within the strike price corridor from $125.0 to $230.0, throughout the last 30 days.
<h3>Carvana Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741197672_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.35</td>
<td>$6.3</td>
<td>$6.35</td>
<td>$190.00</td>
<td>$149.8K</td>
<td>23.6K</td>
<td align="right">19</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.45</td>
<td>$6.3</td>
<td>$6.45</td>
<td>$230.00</td>
<td>$136.7K</td>
<td>637</td>
<td align="right">486</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.75</td>
<td>$6.4</td>
<td>$6.75</td>
<td>$190.00</td>
<td>$130.2K</td>
<td>23.6K</td>
<td align="right">302</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.7</td>
<td>$3.4</td>
<td>$3.7</td>
<td>$125.00</td>
<td>$66.5K</td>
<td>569</td>
<td align="right">83</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.75</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$125.00</td>
<td>$62.9K</td>
<td>569</td>
<td align="right">500</td>
</tr>
</tbody>
</table>

<h3>About Carvana</h3>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
Following our analysis of the options activities associated with Carvana, we pivot to a closer look at the company's own performance.
<h3>Current Position of Carvana</h3>
<ul>
<li>Currently trading with a volume of 1,477,967, the CVNA's price is down by -1.92%, now at $210.97. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 56 days.</li>
</ul>
<h3>Professional Analyst Ratings for Carvana</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $302.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Stephens &amp; Co. downgraded its rating to Overweight, setting a price target of $300. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Neutral rating on Carvana with a target price of $250. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Carvana, which currently sits at a price target of $340. 
&#x2A; In a cautious move, an analyst from Stephens &amp; Co. downgraded its rating to Overweight, setting a price target of $300. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Carvana, targeting a price of $320. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Carvana options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

CVNA

Carvana's Options: A Look at What the Big Money is Thinking

Throughout the last three months, 4 analysts have evaluated Viatris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Viatris and provided 12-month price targets. The average target is $10.75, accompanied by a high estimate of $14.00 and a low estimate of $9.00. This current average has decreased by 14.0% from the previous average price target of $12.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1741197657_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Viatris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Viatris. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viatris compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Viatris's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Viatris's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VTRS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Viatris analyst ratings.</a>
<h2>All You Need to Know About Viatris</h2>
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
<h3>Financial Milestones: Viatris's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Viatris's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -8.06% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Viatris's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -14.64%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Viatris's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -2.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Viatris's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.2%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Viatris's debt-to-equity ratio is below the industry average at 0.77, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VTRS

Forecasting The Future: 4 Analyst Projections For Viatris

Press Releases

10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Earnings

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

BRKR

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

10x Genomics

Interés en corto

10x Genomics (NASDAQ:TXG) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL